7 April 2025

Big Technologies plc

("Big Technologies" or "the Company", together with its subsidiaries the "Group")

Appointment of Ian Johnson as a Non-Executive Director of the Company

The Company is pleased to announce that it has appointed Ian Johnson to the Board of the Company as a Non-Executive Director with immediate effect.

The appointment follows discussions in recent days with Harwood Capital, who contacted the Company stating that they had consulted with certain shareholders who together have a meaningful interest in the Company.  As part of those discussions, Ian Johnson was introduced to the Board.

The Company has received a letter of comfort from Ian Johnson which, among other things, provides a confirmation that he has never met or spoken to Sara Murray and has no connection to her or any of the entities subject to the proceedings filed by the Company in the High Court on 31 March 2025.

Alexander Brennan, Chairman of the Company, said: "I am pleased to welcome Ian to the Board as we focus on finalising our year end accounts, growing our business this year, and building value for all of our stakeholders. The range of Ian's board and industry experience will be invaluable to us in all these contexts as we move forward."

Biography of Ian Johnson

Ian has spent his business career in life science and was founder and CEO of Biotrace International PLC, which was a listed company until its sale to 3M in December 2006. In addition to his current role as Executive Chairman of NIOX Group plc, Ian is also Senior Independent Director of Induction Healthcare Group plc.

Previous appointments include Executive Chairman of Bioquell PLC, non-executive Chairman of Redcentric plc, Quantum Pharma PLC, Cyprotex PLC and Celsis Group Ltd., Senior Independent Director of Clinigen plc and Non-Executive Director of Ergomed PLC. He has also served on the boards of various other public and private companies including AIM listed companies; Evans Analytical Group and AOI Medical Inc.

Ian studied at Cardiff University obtaining a B.Sc. and M.Sc. in Microbiology. He is a Chartered Biologist, a Fellow of the Royal Society of Biology and a member of the Institute of Directors.

Information required to be disclosed by the Company under Rule 17 of the AIM Rules for Companies

Ian Roy Johnson, aged 71, is, or has been, a director or partner of the following companies or partnerships within the past five years:

Ian Johnson owns no shares in the Company.

Ian Johnson was appointed director of Pure Options Solutions Limited in December 2009. Pure Options Solutions Limited subsequently entered into administration in November 2010 and the company was dissolved following liquidation in September 2014. The estimated deficiency to investors and creditors was approximately £4.5 million.

Ian Johnson was appointed director of Toximet Limited in September 2013. Toximet Limited subsequently entered into administration in November 2015, creditors voluntary liquidation in November 2016 and was dissolved following liquidation in August 2017. The estimated deficiency to investors and creditors was approximately £0.8 million.

There are no further disclosures required in accordance with Rule 17 and Schedule Two, paragraph (g) of the AIM Rules for Companies.

Corporate governance information

Ian Johnson will not be considered to be an independent Non-Executive Director under the UK's Quoted Companies Alliance Corporate Governance Guidelines for Small and Mid-Size Quoted Companies given that his appointment was supported by the shareholders referred to above.

Further announcements will be made as appropriate.

Enquiries